GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exagen Inc (NAS:XGN) » Definitions » Gross Margin %

Exagen (Exagen) Gross Margin % : 59.17% (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Exagen Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Exagen's Gross Profit for the three months ended in Dec. 2023 was $8.15 Mil. Exagen's Revenue for the three months ended in Dec. 2023 was $13.77 Mil. Therefore, Exagen's Gross Margin % for the quarter that ended in Dec. 2023 was 59.17%.


The historical rank and industry rank for Exagen's Gross Margin % or its related term are showing as below:

XGN' s Gross Margin % Range Over the Past 10 Years
Min: 7.36   Med: 49.93   Max: 60.55
Current: 56.06


During the past 11 years, the highest Gross Margin % of Exagen was 60.55%. The lowest was 7.36%. And the median was 49.93%.

XGN's Gross Margin % is ranked better than
60.93% of 215 companies
in the Medical Diagnostics & Research industry
Industry Median: 45.52 vs XGN: 56.06

Exagen had a gross margin of 59.17% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Exagen was -0.40% per year.


Exagen Gross Margin % Historical Data

The historical data trend for Exagen's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exagen Gross Margin % Chart

Exagen Annual Data
Trend Dec13 Dec14 Dec15 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 53.43 60.55 57.37 46.86 56.06

Exagen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 50.85 47.23 58.72 57.44 59.17

Competitive Comparison of Exagen's Gross Margin %

For the Diagnostics & Research subindustry, Exagen's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exagen's Gross Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Exagen's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Exagen's Gross Margin % falls into.



Exagen Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Exagen's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=29.5 / 52.548
=(Revenue - Cost of Goods Sold) / Revenue
=(52.548 - 23.092) / 52.548
=56.06 %

Exagen's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=8.1 / 13.765
=(Revenue - Cost of Goods Sold) / Revenue
=(13.765 - 5.62) / 13.765
=59.17 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Exagen  (NAS:XGN) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Exagen had a gross margin of 59.17% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Exagen Gross Margin % Related Terms

Thank you for viewing the detailed overview of Exagen's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Exagen (Exagen) Business Description

Traded in Other Exchanges
Address
1261 Liberty Way, Vista, CA, USA, 92081
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
Executives
John Aballi director, officer: President and CEO C/O DECIPHER BIOSCIENCES, INC., 6925 LUSK BLVD, SUITE 200, SAN DIEGO CA 92121
Paul Kim director 4399 SANTA ANITA AVE, EL MONTE CA 91731
Tullis Growth Fund Ii, L.p. 10 percent owner 11770 US HWY 1, STE 503, PALM BEACH GARDENS FL 33408
Kamal Adawi officer: Chief Financial Officer C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92131
Mark Hazeltine officer: Chief Operating Officer C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Wendy S. Johnson director 800 E. LEIGH STREET, SUITE 209, RICHMOND VA 21219
Tullis James L L director, 10 percent owner 100 FIRST STAMFORD PLACE, STAMFORD CT 06907
Ana Hooker director 441 CHARMANY DRIVE, MADISON WI 53719
Frank Stokes director C/O CASTLE BIOSCIENCES, 820 S. FRIENDSWOOD DRIVE, SUITE 201, FRIENDSWOOD TX 77546
Hunt Holdings Limited Partnership 10 percent owner C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Nmsic Co-investment Fund, L.p. 10 percent owner C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Debra Zack officer: Chief Medical Officer C/O EXAGEN, INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
H.i.g. Bio-exagen, L.p. 10 percent owner C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Thierry Dervieux officer: Chief Scientific Officer C/O EXAGEN DIAGNOSTICS, INC., 1261 LIBERTY WAY, VISTA CA 92081
Nmsic Focused Llc 10 percent owner C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081